Synthetic immunogenic glycoconjugate for melanoma immunotherapy
US8680043B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 4, 2010 |
| Grant date | Mar 25, 2014 |
| Priority date | — |
| Expiry date | Nov 4, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention refers to compounds of formula (I) as useful melanoma vaccines' active ingredients. As a matter of fact, compounds of formula (1) are immunogenic artificial antigens, mimetics of GM3 and GM3 lactone, well known tumor associated antigens (TAAs). In addition, the present invention refers to specific antibodies for compounds of formula (I) which are able to bind to the TAAs. The hereinabove reported compounds and antibodies are therefore potentially useful respectively for the active and passive immunization against tumors over-expressing GM3 ganglioside, in a preferred embodiment melanoma and colon cancer, and for their diagnosis and prognosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.